Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASA 81mg vs 325mg in BCVI
NCT06383650Phase 1Not yet recruiting
- Sponsor
- London Health Sciences Centre
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised trial of aspirin in blunt cerebrovascular injury (BCVI) (2 arms), sponsored by London Health Sciences Centre. Primary endpoint: Study feasibility at 1 year. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
aspirin
03
Conditions
blunt cerebrovascular injury (BCVI)
Beyond the preview
Go deeper on NCT06383650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383650.